Ranibizumab rapidly and sustainably improved vision, reduced the risk of further vision loss, and improved macular edema in patients with DME, with low rates of ocular and nonocular harm.
2012-04-04
Eng.
Ophthalmology
Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Ophthalmology. 2012 Apr;119(4):789-801
© Galenicom 1999-2013